.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Immunotherapy has revolutionized the management of liver cancer. Recent research highlights significant breakthroughs in advanced HCC immunotherapy survival, suggesting that a subset of patients may even achieve a functional cure. By using mixture cure models, researchers can now estimate the proportion of long-term survivors who reach a stable plateau in their survival curves.
Data from pivotal phase 3 trials provide a clearer picture of these outcomes. In the HIMALAYA trial, the combination of durvalumab and tremelimumab resulted in a 12.8% long-term survival rate after five years. This significantly outperformed sorafenib, which showed only 5.2%. Similarly, the RATIONALE-301 trial demonstrated that tislelizumab monotherapy achieved a 25.2% long-term survival rate.
The CheckMate9DW study also offered promising insights into the cure fraction. This trial compared nivolumab-ipilimumab against standard tyrosine kinase inhibitors. The results indicated a cure fraction of 17.8% for the immunotherapy group, while the control group reached only 3.5%. These findings suggest that dual checkpoint inhibition significantly enhances the likelihood of durable remission.
Clinical practice data often differ from controlled trials. However, a large cohort of 1,581 patients treated with atezolizumab-bevacizumab mirrored these trial results. In this real-world setting, long-term survival was 12.3%, and the cure fraction stood at 7.9%.
Identifying which patients will benefit most is crucial. Analysis shows that the ALBI score and the presence of hepatitis C are strong predictors of long-term survival. Additionally, albumin levels and hepatitis C status help clinicians estimate the potential cure fraction. Consequently, these biomarkers allow for more personalized treatment planning in oncology.
A cure fraction refers to the estimated proportion of patients who experience long-term, stable survival without disease progression, effectively reaching a plateau where their mortality risk aligns with the general population.
Combinations like durvalumab-tremelimumab and nivolumab-ipilimumab have demonstrated superior long-term survival and higher cure fractions compared to traditional sorafenib or lenvatinib treatments.
Real-world data for atezolizumab-bevacizumab show a long-term survival rate of approximately 12.3%, which is highly consistent with the 10-15% range observed across various major clinical trials.
Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Evidence from clinical trials and real-world data shows that immunotherapy combinations achieve 10-15% long-term survival and 7-9% cure fractions in advance...
4 months ago
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
